Crescita Therapeutics Inc. (CRRTF)
OTCMKTS · Delayed Price · Currency is USD
0.3300
0.00 (0.00%)
At close: Jul 7, 2025
Crescita Therapeutics Revenue
Crescita Therapeutics had revenue of 3.54M CAD in the quarter ending March 31, 2025, a decrease of -29.20%. This brings the company's revenue in the last twelve months to 18.12M, up 1.14% year-over-year. In the year 2024, Crescita Therapeutics had annual revenue of 19.58M with 11.75% growth.
Revenue (ttm)
18.12M CAD
Revenue Growth
+1.14%
P/S Ratio
0.51
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.41M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 19.58M | 2.06M | 11.75% |
Dec 31, 2023 | 17.52M | -6.00M | -25.52% |
Dec 31, 2022 | 23.53M | 6.76M | 40.29% |
Dec 31, 2021 | 16.77M | 1.13M | 7.22% |
Dec 31, 2020 | 15.64M | -6.70M | -29.98% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Crescita Therapeutics News
- 6 weeks ago - Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders - Financial Post
- 6 weeks ago - Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders - Business Wire
- 2 months ago - Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis® - Financial Post
- 2 months ago - Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis® - Business Wire
- 2 months ago - Crescita Reports First Quarter 2025 Results - Business Wire
- 4 months ago - Crescita Therapeutics GAAP EPS of -C$0.01, revenue of C$6.9M - Seeking Alpha
- 9 months ago - Crescita Reports Third Quarter 2024 Results - Business Wire
- 10 months ago - Crescita Therapeutics Announces Approval of Normal Course Issuer Bid - Business Wire